HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compound...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ISHIOKA, Hiroki KAWAGUCHI, Kenichi KAWAMINAMI, Eiji IMAIZUMI, Tomoyoshi MORIKAWA, Takahiro INAMURA, Kohei KURAMOTO, Kazuyuki TAKAHASHI, Fumie WATANABE, Hideyuki HAMAGUCHI, Hisao NAGASHIMA, Takeyuki YOSHINARI, Tomohiro |
| description | To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2023231912A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2023231912A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2023231912A13</originalsourceid><addsrcrecordid>eNqNyr0KwjAQAOAuDqK-w4GzYJLJMVx-GrV3JV6GTqVInEQL9f1x8QGcvuVbN-fWi8-MA14TAnLXcyEHgTMkcgUTRXA-ZuusJCbgAFFpB10RSwKXbG_QZxafaNusHtNzqbufm2YfvGB7qPN7rMs83eurfkZb9FEbbdRJaavMf-sLAq0t_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><source>esp@cenet</source><creator>ISHIOKA, Hiroki ; KAWAGUCHI, Kenichi ; KAWAMINAMI, Eiji ; IMAIZUMI, Tomoyoshi ; MORIKAWA, Takahiro ; INAMURA, Kohei ; KURAMOTO, Kazuyuki ; TAKAHASHI, Fumie ; WATANABE, Hideyuki ; HAMAGUCHI, Hisao ; NAGASHIMA, Takeyuki ; YOSHINARI, Tomohiro</creator><creatorcontrib>ISHIOKA, Hiroki ; KAWAGUCHI, Kenichi ; KAWAMINAMI, Eiji ; IMAIZUMI, Tomoyoshi ; MORIKAWA, Takahiro ; INAMURA, Kohei ; KURAMOTO, Kazuyuki ; TAKAHASHI, Fumie ; WATANABE, Hideyuki ; HAMAGUCHI, Hisao ; NAGASHIMA, Takeyuki ; YOSHINARI, Tomohiro</creatorcontrib><description>To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240815&DB=EPODOC&CC=AU&NR=2023231912A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240815&DB=EPODOC&CC=AU&NR=2023231912A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ISHIOKA, Hiroki</creatorcontrib><creatorcontrib>KAWAGUCHI, Kenichi</creatorcontrib><creatorcontrib>KAWAMINAMI, Eiji</creatorcontrib><creatorcontrib>IMAIZUMI, Tomoyoshi</creatorcontrib><creatorcontrib>MORIKAWA, Takahiro</creatorcontrib><creatorcontrib>INAMURA, Kohei</creatorcontrib><creatorcontrib>KURAMOTO, Kazuyuki</creatorcontrib><creatorcontrib>TAKAHASHI, Fumie</creatorcontrib><creatorcontrib>WATANABE, Hideyuki</creatorcontrib><creatorcontrib>HAMAGUCHI, Hisao</creatorcontrib><creatorcontrib>NAGASHIMA, Takeyuki</creatorcontrib><creatorcontrib>YOSHINARI, Tomohiro</creatorcontrib><title>HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><description>To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyr0KwjAQAOAuDqK-w4GzYJLJMVx-GrV3JV6GTqVInEQL9f1x8QGcvuVbN-fWi8-MA14TAnLXcyEHgTMkcgUTRXA-ZuusJCbgAFFpB10RSwKXbG_QZxafaNusHtNzqbufm2YfvGB7qPN7rMs83eurfkZb9FEbbdRJaavMf-sLAq0t_g</recordid><startdate>20240815</startdate><enddate>20240815</enddate><creator>ISHIOKA, Hiroki</creator><creator>KAWAGUCHI, Kenichi</creator><creator>KAWAMINAMI, Eiji</creator><creator>IMAIZUMI, Tomoyoshi</creator><creator>MORIKAWA, Takahiro</creator><creator>INAMURA, Kohei</creator><creator>KURAMOTO, Kazuyuki</creator><creator>TAKAHASHI, Fumie</creator><creator>WATANABE, Hideyuki</creator><creator>HAMAGUCHI, Hisao</creator><creator>NAGASHIMA, Takeyuki</creator><creator>YOSHINARI, Tomohiro</creator><scope>EVB</scope></search><sort><creationdate>20240815</creationdate><title>HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><author>ISHIOKA, Hiroki ; KAWAGUCHI, Kenichi ; KAWAMINAMI, Eiji ; IMAIZUMI, Tomoyoshi ; MORIKAWA, Takahiro ; INAMURA, Kohei ; KURAMOTO, Kazuyuki ; TAKAHASHI, Fumie ; WATANABE, Hideyuki ; HAMAGUCHI, Hisao ; NAGASHIMA, Takeyuki ; YOSHINARI, Tomohiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2023231912A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ISHIOKA, Hiroki</creatorcontrib><creatorcontrib>KAWAGUCHI, Kenichi</creatorcontrib><creatorcontrib>KAWAMINAMI, Eiji</creatorcontrib><creatorcontrib>IMAIZUMI, Tomoyoshi</creatorcontrib><creatorcontrib>MORIKAWA, Takahiro</creatorcontrib><creatorcontrib>INAMURA, Kohei</creatorcontrib><creatorcontrib>KURAMOTO, Kazuyuki</creatorcontrib><creatorcontrib>TAKAHASHI, Fumie</creatorcontrib><creatorcontrib>WATANABE, Hideyuki</creatorcontrib><creatorcontrib>HAMAGUCHI, Hisao</creatorcontrib><creatorcontrib>NAGASHIMA, Takeyuki</creatorcontrib><creatorcontrib>YOSHINARI, Tomohiro</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ISHIOKA, Hiroki</au><au>KAWAGUCHI, Kenichi</au><au>KAWAMINAMI, Eiji</au><au>IMAIZUMI, Tomoyoshi</au><au>MORIKAWA, Takahiro</au><au>INAMURA, Kohei</au><au>KURAMOTO, Kazuyuki</au><au>TAKAHASHI, Fumie</au><au>WATANABE, Hideyuki</au><au>HAMAGUCHI, Hisao</au><au>NAGASHIMA, Takeyuki</au><au>YOSHINARI, Tomohiro</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><date>2024-08-15</date><risdate>2024</risdate><abstract>To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2023231912A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A23%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ISHIOKA,%20Hiroki&rft.date=2024-08-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2023231912A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |